Global Ophthalmic Pharmaceutical Drugs Market to Reach US$17 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Ophthalmic Pharmaceutical Drugs. The global market for ophthalmic pharmaceutical drugs is forecast to reach US$17 billion by 2015. Rising incidence as well as prevalence of eye disorders such as macular degeneration, diabetic retinopathy and presbyopia among elderly population, and evolution of treatment options for diseases such as Age-Macular Degeneration, are the key factors driving the market for ophthalmic pharmaceutical drugs.

Ophthalmic Pharmaceutical Drugs: A Global Strategic Business Report

Ophthalmic pharmaceutical drugs is a uniquely competitive market kept perennially vibrant by refining technological changes in drug formulations and efficacy. Conventional drug delivery techniques are giving way to newer, and more effective therapies such as infusion-type medicines, slow-release delivery systems, and implantables. The global market for ophthalmic drugs is witnessing substantial growth, due primarily to factors such as rising incidence as well as prevalence of eye disorders such as macular degeneration, diabetic retinopathy and presbyopia among the elderly population. Growth is also driven by the evolution of treatment options for age-macular degeneration, as well as the ensuing commercial and therapeutic success of Lucentis, which made the market more lucrative and a potential growth sector. Conversely, the market is fraught with challenges, including absence of health insurance among the ageing population in developing countries. Meanwhile, low awareness related to ophthalmic disorders, primarily due to little or no awareness in rural areas, pose tremendous challenges for ophthalmic drugs market in developing countries.

The global ophthalmic drug market is likely to face a patent cliff after 2010 as patents of major products within ocular anti-allergic, anti-glaucoma, as well as anti-inflammatory/anti-inflective therapies expire. The market expansion and the development of ophthalmic franchises of major pharmaceutical providers would be hit by the ensuing generic incursion, along with the rising regulatory priorities with regards to the global healthcare reforms. Though the high efficacy of Allegan/Inspire’s Restasis and Roche/Genetech’s Lucentis is likely to lead the markets for treatment of dry eye and wet Age-Macular Degeneration, respectively, the global ophthalmology treatment sales are expected to stay more or less flat during the ensuing years.

The United States represents the largest market worldwide for ophthalmic pharmaceutical drugs, as stated by the new market research report on Ophthalmic Pharmaceutical Drugs. Europe trails behind the US, followed by Asia-Pacific. Growth-wise, emerging regions such as Asia-Pacific and Latin America are expected to spearhead growth in the global market for ophthalmic pharmaceutical drugs during the analysis period. Glaucoma therapeutics represent the largest market segment. However, Back of Eye treatment drugs are expected to witness the fastest growth through the analysis period 2007-2015.

The global ophthalmic drug market is expected to witness introduction of a range of new therapies beginning 2010, which include complex biotechnological agents, small-molecule anti-infectives and many more. Besides, these therapies are also expected to capitalize on various novel drug delivery systems that is a result of significant growth in technology. Novel products with enhanced safety, tolerability and efficacy are expected to characterize new products launched in the following years.

Major players profiled in the report include Akorn Inc., Alcon Inc., Allergan Inc., Alimera Sciences Inc., Bausch & Lomb Inc., Glaxosmithkline Plc., Inspire Pharmaceuticals Inc., ISTA Pharmaceuticals Inc., Merck & Co. Inc., Novartis Ophthalmics, Opko Health Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Santen Pharmaceutical, among others.

The report titled “Ophthalmic Pharmaceutical Drugs: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the ophthalmic pharmaceutical drugs markets, overview of major drugs, pipeline drugs, patent expiries, current market trends, key growth drivers, recent product approvals, recent product introductions, recent industry activity, and profiles of major/niche global as well as regional market participants. The study analyzes market data and analytics in terms of value sales for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Key segments analyzed in the report include Glaucoma Treatment drugs, Ophthalmic Anti-allergy Drugs, Ophthalmic Anti-infective Drugs, Dry Eye Treatment Drugs, Ophthalmic Anti-inflammatory Drugs, Back of Eye Treatment Drugs, and Other Ophthalmic Treatment Drugs. Also, a seven-year (2000-2006) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Opthalmic_Pharmaceutical_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media